Citadel Advisors
NXTC icon

Citadel Advisors’s NextCure NXTC Stock Holding History

Citadel Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-142
Closed -$817 – 14295
2025
Q1 		$817 Buy
+142
New +$1.25K ﹤0.01% 14211
2024
Q3 		– Sell
-117
Closed -$2.23K – 14926
2024
Q2 		$2.23K Buy
+117
New +$2.27K ﹤0.01% 13719
2024
Q1 		– Sell
-17
Closed -$228 – 15216
2023
Q4 		$228 Sell
17
-108
-86% -$1.56K ﹤0.01% 14084
2023
Q3 		$1.94K Hold
125
– – ﹤0.01% 13784
2023
Q2 		$2.7K Sell
125
-3,992
-97% -$78.6K ﹤0.01% 13757
2023
Q1 		$73.1K Sell
4,117
-1,000
-20% -$19.3K ﹤0.01% 11674
2022
Q4 		$86.6K Buy
5,117
+3,200
+167% +$73.6K ﹤0.01% 11419
2022
Q3 		$63K Sell
1,917
-1,875
-49% -$95.6K ﹤0.01% 11463
2022
Q2 		$214K Buy
+3,792
New +$198K ﹤0.01% 10559
2021
Q2 		– Sell
-875
Closed -$105K – 14178
2021
Q1 		$105K Buy
+875
New +$127K ﹤0.01% 12432
2020
Q4 		– Sell
-1,917
Closed -$202K – 11335
2020
Q3 		$202K Buy
1,917
+667
+53% +$82K ﹤0.01% 8783
2020
Q2 		$322K Buy
+1,250
New +$476K ﹤0.01% 7802
2020
Q1 		– Sell
-650
Closed -$439K – 9987
2019
Q4 		$439K Buy
+650
New +$326K ﹤0.01% 7015

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Citadel Advisors's NXTC Position: Q2 2026 in Review

Citadel Advisors sold out of NextCure (NXTC) in Q2 2026, closing a stake of 15,292 shares — an estimated $161K sold.

Citadel Advisors first reported a position in NXTC in Q2 2019 and held it in 26 quarters. The position peaked at $44.9M in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Citadel Advisors reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,292 NextCure shares in Q2 2026, an estimated $161K.
  • Citadel Advisors first reported a position in NextCure in Q2 2019 and held it in 26 quarters.
  • Citadel Advisors's NextCure position peaked at $44.9M in Q4 2019.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.